FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386221444> ?p ?o ?g. }

• W4386221444 endingPage "13226" @default.
• W4386221444 startingPage "13226" @default.
• W4386221444 abstract "Chronic kidney disease (CKD) progression is associated with persisting oxidative stress, which impairs the NO-sGC-cGMP signaling cascade through the formation of oxidized and heme-free apo-sGC that cannot be activated by NO. Runcaciguat (BAY 1101042) is a novel, potent, and selective sGC activator that binds and activates oxidized and heme-free sGC and thereby restores NO-sGC-cGMP signaling under oxidative stress. Therefore, runcaciguat might represent a very effective treatment option for CKD/DKD. The potential kidney-protective effects of runcaciguat were investigated in ZSF1 rats as a model of CKD/DKD, characterized by hypertension, hyperglycemia, obesity, and insulin resistance. ZSF1 rats were treated daily orally for up to 12 weeks with runcaciguat (1, 3, 10 mg/kg/bid) or placebo. The study endpoints were proteinuria, kidney histopathology, plasma, urinary biomarkers of kidney damage, and gene expression profiling to gain information about relevant pathways affected by runcaciguat. Furthermore, oxidative stress was compared in the ZSF1 rat kidney with kidney samples from DKD patients. Within the duration of the 12-week treatment study, kidney function was significantly decreased in obese ZSF1 rats, indicated by a 20-fold increase in proteinuria, compared to lean ZSF1 rats. Runcaciguat dose-dependently and significantly attenuated the development of proteinuria in ZSF1 rats with reduced uPCR at the end of the study by −19%, −54%, and −70% at 1, 3, and 10 mg/kg/bid, respectively, compared to placebo treatment. Additionally, average blood glucose levels measured as HbA1C, triglycerides, and cholesterol were increased by five times, twenty times, and four times, respectively, in obese ZSF1 compared to lean rats. In obese ZSF1 rats, runcaciguat reduced HbA1c levels by −8%, −34%, and −76%, triglycerides by −42%, −55%, and −71%, and cholesterol by −16%, −17%, and −34%, at 1, 3, and 10 mg/kg/bid, respectively, compared to placebo. Concomitantly, runcaciguat also reduced kidney weights, morphological kidney damage, and urinary and plasma biomarkers of kidney damage. Beneficial effects were accompanied by changes in gene expression that indicate reduced fibrosis and inflammation and suggest improved endothelial stabilization. In summary, the sGC activator runcaciguat significantly prevented a decline in kidney function in a DKD rat model that mimics common comorbidities and conditions of oxidative stress of CKD patients. Thus, runcaciguat represents a promising treatment option for CKD patients, which is in line with recent phase 2 clinical study data, where runcaciguat showed promising efficacy in CKD patients (NCT04507061)." @default.
• W4386221444 created "2023-08-29" @default.
• W4386221444 creator A5002246212 @default.
• W4386221444 creator A5002679231 @default.
• W4386221444 creator A5008943532 @default.
• W4386221444 creator A5011090660 @default.
• W4386221444 creator A5024707341 @default.
• W4386221444 creator A5027047175 @default.
• W4386221444 creator A5042424226 @default.
• W4386221444 creator A5043923684 @default.
• W4386221444 creator A5049468863 @default.
• W4386221444 creator A5049988293 @default.
• W4386221444 creator A5054602698 @default.
• W4386221444 creator A5071793684 @default.
• W4386221444 creator A5079835977 @default.
• W4386221444 creator A5084053909 @default.
• W4386221444 creator A5085170891 @default.
• W4386221444 creator A5088268904 @default.
• W4386221444 creator A5092707854 @default.
• W4386221444 date "2023-08-25" @default.
• W4386221444 modified "2023-10-14" @default.
• W4386221444 title "The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats" @default.
• W4386221444 cites W1533759346 @default.
• W4386221444 cites W2003630942 @default.
• W4386221444 cites W2063071175 @default.
• W4386221444 cites W2076611657 @default.
• W4386221444 cites W2085054033 @default.
• W4386221444 cites W2144245114 @default.
• W4386221444 cites W2184169740 @default.
• W4386221444 cites W2225473766 @default.
• W4386221444 cites W2258349137 @default.
• W4386221444 cites W2338134631 @default.
• W4386221444 cites W2512054829 @default.
• W4386221444 cites W2585229681 @default.
• W4386221444 cites W2617300783 @default.
• W4386221444 cites W2732569562 @default.
• W4386221444 cites W2761086873 @default.
• W4386221444 cites W2913885036 @default.
• W4386221444 cites W2949653893 @default.
• W4386221444 cites W3005957464 @default.
• W4386221444 cites W3010087630 @default.
• W4386221444 cites W3081978010 @default.
• W4386221444 cites W3112831521 @default.
• W4386221444 cites W3154970472 @default.
• W4386221444 cites W3164293639 @default.
• W4386221444 cites W3170911976 @default.
• W4386221444 cites W3200655219 @default.
• W4386221444 cites W3203961952 @default.
• W4386221444 cites W3208523646 @default.
• W4386221444 cites W4210538298 @default.
• W4386221444 cites W4211182277 @default.
• W4386221444 cites W4283587561 @default.
• W4386221444 cites W4311202785 @default.
• W4386221444 cites W4362635536 @default.
• W4386221444 cites W4378191825 @default.
• W4386221444 cites W59187678 @default.
• W4386221444 doi "https://doi.org/10.3390/ijms241713226" @default.
• W4386221444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37686032" @default.
• W4386221444 hasPublicationYear "2023" @default.
• W4386221444 type Work @default.
• W4386221444 citedByCount "0" @default.
• W4386221444 crossrefType "journal-article" @default.
• W4386221444 hasAuthorship W4386221444A5002246212 @default.
• W4386221444 hasAuthorship W4386221444A5002679231 @default.
• W4386221444 hasAuthorship W4386221444A5008943532 @default.
• W4386221444 hasAuthorship W4386221444A5011090660 @default.
• W4386221444 hasAuthorship W4386221444A5024707341 @default.
• W4386221444 hasAuthorship W4386221444A5027047175 @default.
• W4386221444 hasAuthorship W4386221444A5042424226 @default.
• W4386221444 hasAuthorship W4386221444A5043923684 @default.
• W4386221444 hasAuthorship W4386221444A5049468863 @default.
• W4386221444 hasAuthorship W4386221444A5049988293 @default.
• W4386221444 hasAuthorship W4386221444A5054602698 @default.
• W4386221444 hasAuthorship W4386221444A5071793684 @default.
• W4386221444 hasAuthorship W4386221444A5079835977 @default.
• W4386221444 hasAuthorship W4386221444A5084053909 @default.
• W4386221444 hasAuthorship W4386221444A5085170891 @default.
• W4386221444 hasAuthorship W4386221444A5088268904 @default.
• W4386221444 hasAuthorship W4386221444A5092707854 @default.
• W4386221444 hasBestOaLocation W43862214441 @default.
• W4386221444 hasConcept C126322002 @default.
• W4386221444 hasConcept C134018914 @default.
• W4386221444 hasConcept C159641895 @default.
• W4386221444 hasConcept C170493617 @default.
• W4386221444 hasConcept C2776151105 @default.
• W4386221444 hasConcept C2778653478 @default.
• W4386221444 hasConcept C2779561371 @default.
• W4386221444 hasConcept C2780091579 @default.
• W4386221444 hasConcept C71924100 @default.
• W4386221444 hasConcept C88045685 @default.
• W4386221444 hasConcept C98274493 @default.
• W4386221444 hasConceptScore W4386221444C126322002 @default.
• W4386221444 hasConceptScore W4386221444C134018914 @default.
• W4386221444 hasConceptScore W4386221444C159641895 @default.
• W4386221444 hasConceptScore W4386221444C170493617 @default.
• W4386221444 hasConceptScore W4386221444C2776151105 @default.
• W4386221444 hasConceptScore W4386221444C2778653478 @default.
• W4386221444 hasConceptScore W4386221444C2779561371 @default.

• next